Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD

Antonio Anzueto, Marc Miravitlles

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) are associated with significant healthcare costs and contribute to the progress of the disease. Although a number of factors may trigger these episodes, between 40% and 60% are bacterial in nature. Antimicrobial therapy can be effective in treating exacerbations, leading to improved peak expiratory flow rates, fewer hospitalizations, lower relapse rates, and greater clinical success. Evidence suggests that short-course antimicrobial therapy can be as effective as standard duration therapy (>7 days) in treating exacerbations. Randomized trials have shown that clinical and bacteriological success rates are comparable with both 5-day and standard antibiotic courses. Furthermore, 5-day fluoroquinolone therapy is associated with faster recovery, fewer relapses, prolonged duration between episodes, and less hospitalization when compared with standard therapy. Both moxifloxacin and gemifloxacin have received FDA-approval for 5-day therapy in AECB.

Original languageEnglish (US)
Pages (from-to)1396-1403
Number of pages8
JournalRespiratory Medicine
Issue number10
StatePublished - Oct 2010


  • AECB
  • COPD
  • Chronic bronchitis
  • Duration of therapy
  • Fluoroquinolones
  • Short-course therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD'. Together they form a unique fingerprint.

Cite this